NIKOLAUS S. TREDE
Medical Practice at Medical Dr, Salt Lake City, UT
License number
Utah 5688955-1205
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
100 N Medical Dr, Salt Lake City, UT 84113
Phone
(801) 581-2121
(801) 213-3800
(801) 213-3800
Personal information
See more information about NIKOLAUS S. TREDE at radaris.comName
Address
Phone
S Salt Lake, UT
156 Lincoln St, Salt Lake Cty, UT 84102
273 1St Ave, Salt Lake City, UT 84103
273 1St Ave, Salt Lake City, UT 84103
Professional information
Nikolaus Sebastin Trede, Salt Lake City UT
Specialties:
Internal Medicine, Hematology & Oncology, Medical Oncology, Pediatrics, Pediatric Hematology-Oncology
Work:
Primary Children+s Medical Center
100 Mario Capecchi Dr, Salt Lake City, UT 84113 University of Utah Huntsman Cancer
2000 Circle Of Hope Dr, Salt Lake City, UT 84112
100 Mario Capecchi Dr, Salt Lake City, UT 84113 University of Utah Huntsman Cancer
2000 Circle Of Hope Dr, Salt Lake City, UT 84112
Education:
Albert-Ludwigs-Universitaet Freiburg (1987)
Dr. Nikolaus S Trede, Salt Lake City UT - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
PEDIATRIC ONCOLOGY HEMATOLOGY
100 Mario Capecchi Dr SUITE 1400, Salt Lake City 84113
(801) 662-1000 (Phone), (801) 588-2662 (Fax)
100 Mario Capecchi Dr SUITE 1400, Salt Lake City 84113
(801) 662-1000 (Phone), (801) 588-2662 (Fax)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2008, Pediatrics, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Freiburg
University of Freiburg
Compounds For Modulating T-Cells
US Patent:
2008029, Nov 27, 2008
Filed:
Apr 11, 2008
Appl. No.:
12/101690
Inventors:
Nikolaus S. Trede - Salt Lake City UT, US
International Classification:
A61K 31/4402, A61K 31/4439, A61K 31/495, A61K 31/421, A61K 31/52, A61K 31/341, A61K 31/415, A61K 31/4184, A61P 19/02, A61P 25/00
US Classification:
51425503, 514353, 514339, 514338, 514374, 51426333, 514461, 514403, 514395
Abstract:
Disclosed are compounds and compositions that modulate T-cells. Such compounds can be used to treat T-cell mediated disease like T-ALL, rheumatoid arthritis, multiple sclerosis, and graft-vs-host disease (GvHD), to name but a few. The compounds have a general structure as shown in Formula I.wherein Arand Ar, are independent of one another, a substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl; and L is a bond or a linker spanning two, three, four, or five atoms.